Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;37(8):10587-93.
doi: 10.1007/s13277-016-4954-9. Epub 2016 Feb 9.

Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway

Jun Li  1 , Zhangjun Song  2 , Yiyu Wang  3 , Yue Yin  3 , Ying Liu  3 , Rong Yuan  3 , Xing Nan  3
Affiliations
Free article

Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway

Jun Li et al. Tumour Biol. 2016 Aug.
Free article

Retraction in

Abstract

Sphingosine kinase 1 (SphK1) expression is elevated in various cancers and is associated with shorter survival times for patients. However, the molecular mechanism of SphK1 up-regulation in triple-negative breast cancer (TNBC) remains unclear. In this study, we assayed the expression level of SphK1 in TNBC tissues by qRT-PCR and immunohistochemistry. The level of S1P was quantified by ELISA in the serum of TNBC patients. Our results found that the levels of SphK1 and S1P were significantly increased in TNBC patients compared with normal control. Furthermore, knockdown of SphK1 with siRNA decreased TNBC cell proliferation and inhibited cell migration/invasion. These data suggest that SphK1 has an important role in TNBC and presents an attractive therapeutic target for the treatment for TNBC.

Keywords: AKT; Chemotherapy; PI3K; Sphingosine kinase 1; Sphingosine-1-phosphate; Triple-negative breast cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Oncotarget. 2015 Dec 1;6(38):41360-9 - PubMed
    1. Eur J Cancer. 2010 Dec;46(18):3417-24 - PubMed
    1. Nature. 2000 Aug 17;406(6797):747-52 - PubMed
    1. Mol Cancer Ther. 2015 Oct;14(10):2303-12 - PubMed
    1. Biochim Biophys Acta. 2006 Dec;1758(12):2016-26 - PubMed

Publication types

MeSH terms

LinkOut - more resources